Warning letters, 483s, Recalls, Import Alerts, Audit observations
The USFDA has placed Dabur’s Dadra and Nager Haveli facility under Import Alert 66-40 in
The USFDA issued a Form 483 to Strides Pharma Sciences Ltd., Bangalore facility (FEI 3004554612)
The U.S. FDA has issued a Warning Letter to Simtra BioPharma Solutions following cGMP deviations
USFDA Inspection of Pharmathen’s Rodopi facility in Greece (FEI 3009961173) resulted in issuance of Form
The USFDA has classified Sun Pharma’s Baska (Halol) facility (FEI: 3002957541) as Official Action Indicated
Novo Nordisk owned Catalent Indiana sterile products formulation facility was inspected by USFDA in June
The FDA inspected Colgate-Palmolive/Tom’s of Maine, Inc’s Sanford facility in the US in May 2024.
The USFDA issued a warning letter in January 2025 to Sanofi’s API facility in Framingham,
Indoco Remedies’ Goa Plant (FEI 3005124189) received a warning letter from the FDA following critical
The USFDA has issued a Warning Letter to Hyderabad-based OTC manufacturer Akron Formulations for critical
